Liver impairment drug study completed: what happens to BPN14770?

NCT ID NCT07018492

Completed Knowledge-focused Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how the drug BPN14770 is handled by the body in people with mild, moderate, or severe liver impairment compared to healthy people. A total of 32 adults took a single dose of the drug. Researchers measured drug levels in the blood and checked for side effects. The goal was to understand if liver problems change how the drug works, which is important for future safe use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BPN14770
What this could lead to: If successful, this study will help determine safe dosing of BPN14770 for people with liver problems, potentially guiding future treatment use.
What could go wrong: This is an early phase 1 study with only 32 people. It focuses on drug processing, not on treating any disease, so it may not lead to a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT

Contacts and locations

Locations

Division of Clinical Pharmacology, University of Miami

Miami, Florida, 33136, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Texas Liver Institute

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.